Stewart A, Hickman M, Agius P, Scott N, Stone J, Roxburgh A
BMJ Open. 2025; 15(2):e091337.
PMID: 39933808
PMC: 11815420.
DOI: 10.1136/bmjopen-2024-091337.
Nicholls J, Masterton W, Falzon D, McAuley A, Carver H, Skivington K
Harm Reduct J. 2025; 22(1):6.
PMID: 39806415
PMC: 11730151.
DOI: 10.1186/s12954-024-01144-1.
Cui Z, Karamouzian M, Law M, Hayashi K, Milloy M, Kerr T
Int J Ment Health Addict. 2024; 22(6):4004-4020.
PMID: 39722780
PMC: 11666779.
DOI: 10.1007/s11469-023-01098-8.
Owczarzak J, Martin E, Weicker N, Evans I, Morris M, Sherman S
Harm Reduct J. 2024; 21(1):161.
PMID: 39210459
PMC: 11363392.
DOI: 10.1186/s12954-024-01076-w.
Lim J, Russell W, El-Sheikh M, Buckeridge D, Panagiotoglou D
Harm Reduct J. 2024; 21(1):126.
PMID: 38943164
PMC: 11212409.
DOI: 10.1186/s12954-024-01037-3.
Perceptions of Overdose Response Hotlines and Phone Application Services Among Women and Gender-diverse Individuals Who Use Drugs in Canada: A Qualitative Study.
Lee A, Jafri F, Viste D, Seo B, Skiber D, Medwid M
J Addict Med. 2024; 18(5):553-560.
PMID: 38785357
PMC: 11882170.
DOI: 10.1097/ADM.0000000000001325.
How do people who use opioids express their qualities and capacities? An assessment of attitudes, behaviors, and opportunities.
Ezell J, Pho M, Simek E, Ajayi B, Shetty N, Walters S
Harm Reduct J. 2024; 21(1):79.
PMID: 38589920
PMC: 11000313.
DOI: 10.1186/s12954-024-00981-4.
Crystal methamphetamine use and methadone maintenance treatment dissatisfaction: A prospective cohort study in Vancouver, Canada.
Cui Z, Hayashi K, Bach P, Milloy M, Kerr T
J Subst Use Addict Treat. 2023; 151:208956.
PMID: 36804867
PMC: 10810610.
DOI: 10.1016/j.josat.2023.208956.
Self-injecting non-prescribed substances into vascular access devices: a case study of one health system's ongoing journey from clinical concern to practice and policy response.
Chase J, Nicholson M, Dogherty E, Garrod E, Hill J, Brar R
Harm Reduct J. 2022; 19(1):130.
PMID: 36424629
PMC: 9694828.
DOI: 10.1186/s12954-022-00707-4.
Difficulty accessing supervised consumption services during the COVID-19 pandemic among people who use drugs in Vancouver, Canada.
Cassie R, Hayashi K, DeBeck K, Milloy M, Cui Z, Strike C
Harm Reduct J. 2022; 19(1):126.
PMID: 36401299
PMC: 9675060.
DOI: 10.1186/s12954-022-00712-7.
Opioid agonist therapy engagement and crystal methamphetamine use: The impact of unregulated opioid use in Vancouver, Canada.
Cui Z, Bach P, Ti L, Hayashi K, Morgan J, Milloy M
Int J Drug Policy. 2022; 110:103879.
PMID: 36265327
PMC: 9886012.
DOI: 10.1016/j.drugpo.2022.103879.
Predictors of crystal methamphetamine use initiation or re-initiation among people receiving opioid agonist therapy: A prospective cohort study.
Cui Z, Hayashi K, Bach P, Dong H, Milloy M, Kerr T
Drug Alcohol Depend. 2022; 240:109624.
PMID: 36116155
PMC: 9886065.
DOI: 10.1016/j.drugalcdep.2022.109624.
An avoidable crisis.
Matheson C, Robertson R
Harm Reduct J. 2022; 19(1):98.
PMID: 36038934
PMC: 9422131.
DOI: 10.1186/s12954-022-00680-y.
6th Canadian Symposium on Hepatitis C Virus: Delivering a cure for hepatitis C infection-What are the remaining gaps?.
Khan S, Bernier A, Dapp D, Fortier E, Krajden M, King A
Can Liver J. 2022; 1(2):94-105.
PMID: 35990718
PMC: 9202794.
DOI: 10.3138/canlivj.1.2.008.
NIMBYism and Harm Reduction Programs: Results from Baltimore City.
Rouhani S, Schneider K, Weicker N, Whaley S, Morris M, Sherman S
J Urban Health. 2022; 99(4):717-722.
PMID: 35641715
PMC: 9154206.
DOI: 10.1007/s11524-022-00641-7.
Service utilization patterns and characteristics among clients of integrated supervised consumption sites in Toronto, Canada.
Nassau T, Kolla G, Mason K, Hopkins S, Tookey P, McLean E
Harm Reduct J. 2022; 19(1):33.
PMID: 35351160
PMC: 8966307.
DOI: 10.1186/s12954-022-00610-y.
Drug Consumption Rooms: Welfare State and Diversity in Social Acceptance in Denmark and in France.
Houborg E, Jauffret-Roustide M
Am J Public Health. 2022; 112(S2):S159-S165.
PMID: 35349316
PMC: 8965187.
DOI: 10.2105/AJPH.2022.306808.
Six Moments of Infection Prevention in Injection Drug Use: An Educational Toolkit for Clinicians.
Harvey L, Boudreau J, Sliwinski S, Strymish J, Gifford A, Hyde J
Open Forum Infect Dis. 2022; 9(2):ofab631.
PMID: 35097153
PMC: 8794071.
DOI: 10.1093/ofid/ofab631.
Health impacts of a scale-up of supervised injection services in a Canadian setting: an interrupted time series analysis.
Kennedy M, Hayashi K, Milloy M, Compton M, Kerr T
Addiction. 2021; 117(4):986-997.
PMID: 34854162
PMC: 8904318.
DOI: 10.1111/add.15717.
Supervised Injection Facilities as Harm Reduction: A Systematic Review.
Levengood T, Yoon G, Davoust M, Ogden S, Marshall B, Cahill S
Am J Prev Med. 2021; 61(5):738-749.
PMID: 34218964
PMC: 8541900.
DOI: 10.1016/j.amepre.2021.04.017.